Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case–Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4) - Sorbonne Université
Article Dans Une Revue Journal of Acquired Immune Deficiency Syndromes - JAIDS Année : 2019

Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case–Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4)

Résumé

BACKGROUND: HIV-infected patients have lower bone mineral density and a higher incidence of fractures than the general population of the same age and sex. To assess the impact of antiretroviral (ARV) drugs exposure on the risk of osteoporotic fractures, we conducted a nested case-control study. METHODS: Cases were individuals enrolled while ARV-naive, with a first prospectively recorded fracture between 2000 and 2010. Controls were randomly selected after matching for sex, age (±3 years), period of HIV diagnosis (<1997/≥1997), and clinical center. The risk of fracture was analyzed with conditional logistic regression models, using different ways to model ARV exposure. All exposure variables and potential confounders were included in multivariable models. RESULTS: Among 861 reviewed cases, 261 fractures were osteoporotic and 254 of cases were matched to at least one control (376 controls). The median year of fracture diagnosis was 2007 (interquartile range 2004-2009): 49% of patients had been exposed to tenofovir disoproxil fumarate (TDF) and 82% to protease inhibitors (PIs). After taking into account the transmission group, AIDS status, geographic origin, body mass index, current smoking status, alcohol consumption, exposure to systemic glucocorticoids, and the period of enrollment, there was no association between the risk of fracture and exposure to TDF [odds ratio for cumulative exposure: 1.04 (0.86-1.27), similar results for ever-exposed subjects], to nucleoside reverse transcriptase inhibitors, or to PIs [odds ratio for cumulative PI exposure: 1.02 (0.92-1.12)]. CONCLUSIONS: We found no evidence of an excess risk of fracture after exposure to TDF or PIs. This has important implications for the debate concerning tenofovir alafenamide versus generic TDF.
Fichier principal
Vignette du fichier
Costagliola et al. - 2019 - Impact of Antiretroviral Drugs on Fracture Risk in.pdf (513.75 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02291243 , version 1 (18-09-2019)

Identifiants

Citer

Dominique Costagliola, Valérie Potard, Sylvie Lang, Sophie Abgrall, Claudine Duvivier, et al.. Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case–Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4). Journal of Acquired Immune Deficiency Syndromes - JAIDS, 2019, 80 (2), pp.214-223. ⟨10.1097/QAI.0000000000001903⟩. ⟨hal-02291243⟩
365 Consultations
294 Téléchargements

Altmetric

Partager

More